The Effectiveness of PET scan Technology in Diagnosis and Treatment of Non-Small Cell Lung Carcinoma (NSCLC) and Lymphoma: A Systematic Review of Literature
,
Abstract
Background: Positron emission tomography (PET) scan is a non-invasive, complicated and expensive medical imaging technology used for diagnosis and treatment of various diseases including cancers. This study aimed to evaluate the safety and effectiveness of this technology in Iran.Methods: The major medical electronic databases including Cochrane Library, Google Scholar, MEDLINE and IranMedex were searched. Studies that compared PET scan with another diagnostic method in terms of sensitivity, specificity and safety were used.Findings: PET scan has been found to be a non-invasive and safe procedure for diagnosing metastatic NSCLC with a sensitivity and specificity of 74% to 95% and 81% to 97%, respectively. On the other hand, the sensitivity and specificity of computed tomography (CT) scan have been reported as 60% to 67% and 73% to 77%, respectively. The corresponding values for mediastinoscopy have been 78% and 100%. In lymphoma, the specificity and sensitivity of PET scan (90% and 79% to 100%, respectively) have been higher than those of gamma scan. Although PET scan is not an appropriate method for screening and diagnosing cancer, it can contribute to staging and follow-up processes incases of NSCLC and lymphoma. This technology adds 0.046 years (about 17 days) to the patient’s life.Conclusion: PET scan is a safe technology that has better diagnostic performance compared to similar technologies. The application of this method in staging and follow-up of NSCLC and lymphoma can prevent unnecessary surgeries and adds a few years to patients’ longevity and quality of life.Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care 2007; 23(1): 30-5.
Department of Health. A framework for the development of Positron Emission Tomography (PET) services in England [Online] 2005. Avail- able from: URL: http://webarchive.nationalarchives.gov.uk/+/http:// www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/ documents/digitalasset/dh_4121030.pdf.
Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected can- cers. Health Technol Assess 2007; 11(44): iii-267.
Abbasidezfuli A, Adhami Sh, Javaherzadeh M, Daneshvar A, Pejhan S, Arab M, et al.. Role of operation in lung cancer. Journal of Kordestan University of Medical Sciences 2004; 8(3): 5967. [In Persian].
Medicare Services Advisory Committee. Positron Emission Tomog- raphy. Part 2(ii). Canberra: Medicare Services Advisory Committee; 2001.
American Cancer Society.Lung Cancer (NonSmall Cell) [Online] 2007. [cited 2007 Oct 31]; Available from: URL: http://www.cancer. org/
Cleemput I, Dargent G, Poelmans J, Camberlin C, Van Del Burel A, Ramaekers D. HTA Tomographie par Emission de Positrons en Bel- gique. KCE Reports; 2005. p. 22
Laupacis A. Health Technology Assessment of PET. Toronto: Insti- tute for Clinical Evaluative Sciences (ICES); 2001.
Danish Centre for Evaluation and Health Technology Assessment. Positron Emission Tomography (PET) with 18-FFluorodeoxyglucose 34 Basic & Clinical Cancer Research, 2014; 6(3): 29-35 www.bccrjournal.com (FDG). A Literature Review of Evidence for Clinical use in the Fields of Oncology, Cardiology and Neurology. Copenhagen: DACEHTA; 2001.
Bourguet P, Bosquet L, Corone C, Devillers A, Foehrenbach H, Lumbroso JD, et al.. Recommendations for clinical practice: Standards, Options and Recommendations for utilization of positron emission to- mography with [18F]-FDG (FDG-PET) in oncology (full report). Paris: FNCLCC,Recommendations for clinical practice. [Online] 2003. Avail- able from URL: http://www.fnclcc.fr/, 2003.
HTBS-HTA (Health Technology Board for Scotland). Posi- tron Emission Tomography (PET) Imaging in Cancer Management. Glasgow: Health Technology Board for Scotland (HTBS) (merged into NHS Quality Improvement Scotland (NHS QIS); 2002.
AETMIS. Positron emission tomography in Quebec. Montreal [On- line] 2003. Available from URL: http://www.aetmis.gouv.qc.ca, 2003.
Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, et al.. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lym- phoma: a blinded comparison. Leuk Lymphoma 2004; 45(1): 85-92.
Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al.. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 2003; 14(1): 123-30.
Dobert N, Menzel C, Berner U, Hamscho N, Wordehoff N, Mitrou P, et al.. Positron emission tomography in patients with Hodgkin’s disease: correlation to histopathologic subtypes. Cancer Biother Radiopharm 2003; 18(4): 565-71.
Itti E, Haioun C, Rahmouni A, Reyes F, Meignan M. Agressive large cell lymphoma: early assessment of therapeutic efficacy by positron emission tomography. Medecine Nucleaire 2004; 28(7): 327-32.
Zinzani PL, Chierichetti F, Zompatori M, Tani M, Stefoni V, Gar- raffa G, et al.. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 2002; 43(6): 1239-43.
Hicks RJ, Binns DS, Fawcett ME, Ware RE, Kalff V, McKenzie AF, et al.. Positron emission tomography (PET): experience with a largefield-of-view three-dimensional PET scanner. Med J Aust 1999; 171(10): 529-32.
NHS Quality Improvement Scotland. HTA Report 2: Positron emis- sion tomography (PET) imaging in cancer management; Understanding HTBS Advice; Use of PET imaging for cancer in Scotland. Amendment to full report published July 2005. Glasgow: National Institue for Health Research; 2005.
| Files | ||
| Issue | Vol 6 No 3 (2014) | |
| Section | Reviews | |
| Keywords | ||
| PET scan NSCLC Lymphoma Imaging | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
